A distinct "side population" of cells in human tumor cells: Implications for tumor biology and therapy

Cell Cycle

Volumn 4, Issue 2, 2005, Pages 206-208

  Hirschmann Jax, C ^a,b   Foster, A E ^a   Wulf, G G ^a,c   Goodell, M A ^a   Brenner, M K ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cancer stem cell; Drug resistence; Hoechst 33342; Side population

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOSTATIC AGENT; FLUORESCENT DYE; MITOXANTRONE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; BREAST ADENOCARCINOMA; CANCER CELL; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LIPOPHILICITY; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; RECURRENT DISEASE; SHORT SURVEY; SOLID TUMOR; STEM CELL; TUMOR CELL;

MAMMALIA;

EID: 25444458009     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.2.1406     Document Type: Short Survey

References (40)

1. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Ann Rev Cell Dev Biol 1995; 11:35-71.
2. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81:2844-53.
3. Orlic D, Anderson S, Bodine DM. Biological properties of subpopulations of pluripotent hematopoietic stem cells enriched by elutriation and flow cytometry. Blood Cells 1994; 20:107-17.
4. Varnum-Finney B, Xu L, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch 1 signalling. Nature Med 2000; 6:1278-81.
5. Henrique D, Hirsinger E, Adam J, Le Roux I, Pourquie O, Ish-Horowicz D, Lewis J. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. Curr Biol 1997; 7:661-70.
6. Austin J, Kimble J. Glp-1 is required in the germ line for regulation of the decision between mitosis and meiosis in C. Elegans. Cell 1987; 51:589-99.
7. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, Ling LE, Karanu FN, Bhatia M. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nature Immunol 2001; 2:172-80.
8. Wechsler-Reya RJ, Scott MP. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999; 22:103-14.
9. Zhang Y, Kalderon D. Hedgehog acts as a somatic stem cell factor in Drosophila ovary. Nature 2001; 410:599-604.
10. Zhu AJ, Watt FM. β-catenin signalling modulates proliferative potential of human epidermal keratinocytes independently of intercellular adhesion. Development 1999; 126:2285-98.
11. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H. Depletion of epithelia stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genet 1998; 19:1-5.
12. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumor is caused by activating mutatuions in β-catenin. Nature Gen 1999; 21:410-3.
13. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24:385-428.
14. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66:649-61.
15. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierachy that originates from a primitive hematopoietic cell. Nature Med 1997; 3:730-7.
17. Wulf G, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA. A leukemic stem cell with instrinsic drug efflux capacity in acute myelod leukemia. Blood 2001; 98:1166-73.
18. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. PNAS 2004; 101:781-6.
19. Hirschmann-Jax C, Foster AE, Wulff GG, Nuchtern JG, Jax TW, Gobel U, Goddell MA, Brenner MK. A distinct "side population" of tumor cells with high drug efflux capacity in human tumor cells. PNAS 2004; 101:14228-33.
20. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797-806.
21. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, Johnson RP. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3:1337-45.
22. Asakura A, Rudnicki MA. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp Hematol 2002; 30:1339-45.
23. Wulf GG, Luo KL, Jackson K, Brenner MK, Goodell MA. Cells of the hepatic side population (SP) contribute to liver regeneration and are recruited from the bone marrow. Haematologica 2003; 88:368-78.
24. -/- mice show normal generation, function, and multi-tissue trafficking of primitive hematopoietic cells. Exp Hematol 2002; 30:862-9.
25. Zhou S, Schuetz JD, Bunting KD, Colapietro A-M, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Nat Med 2001; 7:1028-34.
26. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000; 96:365-8.
27. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91:3497-504.
28. Connors TD, Van Raay TJ, Petry LR, Klinger KW, Landes GM, Burn TC. The cloning of a human ABC gene (ABC3) mapping to chromosome 16p13.3. Genomics 1997; 39:231-4.
29. Klugbauer N, Hofmann F. Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein. FEBS Lett 1996; 391:61-5.
30. Broccardo C, Luciani M, Chimini G. The ABCA subclass of mammalian transporters. Biochim Biophys Acta 1999; 1461:395-404.
31. Norwood N, Wang R-Y, Hirschmann-Jax C, Andreeff MK, Brenner MK, Goodell MA, Wulf GG. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leukemia Res 2004; 28:295-9.
32. Wulf GG, Modlich S, Klugbauer N, Inagaki N, Reinhardt D, Griesinger F, Trümper L. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004; 89:1394-5.
33. Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y, Morohoshi T, Ogawa J, Shioda S, Inagaki N. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 2001; 508:221-5.
34. Mulugeta S, Gray JM, Notarfrancesco KL, Gonzales LW, Koval M, Feinstein SI, Ballard PL, Fisher AB, Shuman H. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter Protein ABCA3. J Biol Chem 2002; 277:22147-55.
35. Pluen A, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001; 98:4628-33.
36. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46:149-68.
37. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7:987-9.
38. Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des 1999; 14:153-68.
39. Durand RE, Olive PL. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol 2001; 64:211-33.
40. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473-5.